化疗
医学
宫颈癌
肿瘤科
内科学
免疫系统
癌症
癌症研究
完全响应
宫颈癌
癌症治疗
免疫疗法
梅德林
免疫学
作者
Qin Xu,Zhengrong Deng,Jing Liu,Yanhong Zhuo,Fei Zhu,Lele Chang,Qin Liu,Yajuan Fu,Peiwei Li,Yunyun Liu,Songhua Huang,Li Li,Xingyun Xie,Ying Chen,Yingtao Lin,Lele Zang,Meifang Ke,Li Chen,Xiaoxia Huang,Cong Wang
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2025-11-26
卷期号:16 (3): 439-459
被引量:5
标识
DOI:10.1158/2159-8290.cd-25-1315
摘要
The standard of care for advanced cervical cancer includes chemotherapy, antiangiogenic, and/or immune checkpoint blockade regimens. Although effective, it leads to pleiotropic side effects. Deescalation chemotherapy together with immunotargeted therapies has been proven effective and less toxic in other cancers. In this study, we conducted a multicenter, single-arm, phase II study of first-line deescalated platinum-based chemotherapy plus anlotinib and penpulimab, followed by maintenance therapy solely with anlotinib and penpulimab in patients with PD-L1-positive, persistent, recurrent, or metastatic cervical cancer. Of 32 efficacy-evaluable patients, 30 (93.8%, 95% confidence interval, 79.2%-99.2%) had an investigator-confirmed objective response. Single-nucleus RNA sequencing implied enhanced chemotaxis and proliferative activity of tumor-infiltrating T cells, and activated germinal center B cells portended optimal treatment response. Patients with a high tertiary lymphoid structure-to-tumor area ratio exhibited better survival. Our findings lay the groundwork for the feasibility of first-line de-escalated chemotherapy plus anlotinib and penpulimab in patients with metastatic, persistent, or recurrent cervical cancer. SIGNIFICANCE: We recruited 34 patients with advanced cervical cancer receiving two cycles of platinum-based chemotherapy plus anlotinib and penpulimab, followed by maintenance therapy solely with anlotinib and penpulimab, and showed safety and efficacy of this deescalation regimen. This work highlights the potential for personalized treatment strategies and feasibility of reduced-toxicity regimens.
科研通智能强力驱动
Strongly Powered by AbleSci AI